SCHOTT Pharma, a pioneer in pharmaceutical storage and delivery solutions, is investing more than 100 million euros in its existing site in Lukácsháza, Hungary, to expand capacity for sterile ready-to-use (RTU) cartridges. Following the opening of a production facility for prefillable glass syringes in 2024, the company has now laid the foundation stone for another plant at the site, which will create production capacity for high-value solutions (HVS). This step is part of the company’s expansion strategy to increase the share of these high-margin products in its sales. “To meet growing demand, we are expanding our capacity and presence in the field of diabetes and obesity. That’s why we are investing more than 100 million euros in our plant in Hungary,” said Andreas Reisse, CEO of SCHOTT Pharma. Sterile cartridges are used for the administration of biologics, GLP-1 drugs, insulin, or hormone therapies for the treatment of diabetes, obesity, or immune disorders. The new facility will create more than 100 additional jobs in the region.
The SCHOTT Pharma site in Lukácsháza already plays a key role in supplying the global pharmaceutical industry with solutions for the storage and administration of medications. Just last year, the company opened a new, state-of-the-art production facility for prefillable glass syringes, which are used for GLP-1 medications, critical vaccines, and biologics. Since then, production has commenced with 120 new employees and additional production capacity has been created.
With ready-to-use cartridges, the company plans to create additional production capacity for high-value solutions at the site, which has sufficient space to support the company’s growth strategy. “We would like to express our sincere thanks to the Ministry of Foreign Affairs and Trade for supporting these two expansion projects. Lukácsháza is not only an important location for ensuring supply security for our customers in the region, but also makes an important contribution to SCHOTT Pharma’s global growth strategy,” says Eva Szabó, Site Manager in Lukácsháza.
Building on existing expertise, the high-tech sterile cartridge production facility will be equipped with state-of-the-art machinery to offer the market high-quality sterile products. Furthermore, an advanced washing system and a new steam sterilization process for cartridges will reduce environmental impact. Production will be fully integrated and automated, requiring minimal manual intervention. Following St. Gallen, Switzerland, Lukácsháza will be SCHOTT Pharma’s second sterile cartridge production site.
